相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Statistical Consideration and Challenges in Bridging Study of Personalized Medicine
Meijuan Li
Journal of Biopharmaceutical Statistics (2015)
US Food and Drug Administration Approval: Crizotinib for Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer That Is Anaplastic Lymphoma Kinase Positive
Shakun M. Malik et al.
CLINICAL CANCER RESEARCH (2014)
FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation
Geoffrey Kim et al.
CLINICAL CANCER RESEARCH (2014)
Next-Generation Medicines: Past Regulatory Experience and Considerations for the Future
M. A. Pacanowski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A. McArthur et al.
LANCET ONCOLOGY (2014)
Clinical development success rates for investigational drugs
Michael Hay et al.
NATURE BIOTECHNOLOGY (2014)
FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements
Dickran Kazandjian et al.
ONCOLOGIST (2014)
Identifying a Subpopulation for a Tailored Therapy: Bridging Clinical Efficacy From a Laboratory-Developed Assay to a Validated In Vitro Diagnostic Test Kit
Jonathan S. Denne et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2014)
Analytical and clinical evaluation of biomarkers assays: When are biomarkers ready for prime time?
Gene A. Pennello
CLINICAL TRIALS (2013)
Beyond Exon 2-The Developing Story of RAS Mutations in Colorectal Cancer
Jordan Berlin
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection of BRAF V600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant Melanoma
Steven Anderson et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2012)
Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma
Harkanwal Halait et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2012)
US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics
Reena Philip et al.
BIOANALYSIS (2011)
Clinical Trial Designs for Predictive Biomarker Validation: Theoretical Considerations and Practical Challenges
Sumithra J. Mandrekar et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
Richard M. Simon et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
FDA holds court on post hoc data linking KRAS status to drug response
George S. Mack
NATURE BIOTECHNOLOGY (2009)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Targeting the EGFR pathway for cancer therapy
James B. Johnston et al.
CURRENT MEDICINAL CHEMISTRY (2006)
分享论文
